FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108709967> ?p ?o ?g. }

• W2108709967 endingPage "2875" @default.
• W2108709967 startingPage "2866" @default.
• W2108709967 abstract "More and more patients worldwide suffer from end-stagerenal disease which often is secondary to diabetes (e.g.36.9% of all US patients with end-stage renal disease havea diabetic nephropathy [1]). Indeed, both types of diabetesare burdened by long-term complications, including retin-opathy and nephropathy. Nephropathy occurs in 25–40%of type 1 and type 2 diabetic patients [2], and is character-izedbythepresenceofabnormalamountsofproteinsintheurine, a sign of alteration in the renal filtration capabilitiesof the nephron. In many patients, diabetic nephropathy(DN) progresses to end-stage renal disease. However, it iscurrently impossible to reliably predict which and whendiabetic patients will develop nephropathy and progressto kidney failure. The persistent presence of albumin inthe urine is considered predictive of the subsequent devel-opment and clinical progression of DN [3,4]. Currently,microalbuminuria (MA) is considered the first clinicalevidence of incipient diabetic nephropathy. It is definedas an urinary albumin excretion of 30–300 mg/day andcharacterizes the stage III of diabetic nephropathy accord-ing to Mogensen’s classification [5]. However, despite itscapacity to highlight nephron damage, MA is a non-spe-cific marker of DN especially in subjects with type 2 dia-betes. Indeed, only 30–45% of microalbuminuric type 2diabetic patients will develop overt proteinuria over morethan 10 years [6], and MA is also proposed as a markerof high cardiovascular risk in diabetic and non-diabeticpatients [7], as recently highlighted [8]. Thus, MA shouldnot be considered an early and specific marker of DN.Urineandplasmaproteomicshavegainedmuchattentionas tools for the identification of diagnostic and prognosticbiomarkers of renal diseases. For many years now, it hasbeen hoped that proteomic methods would unveil earlierandmorespecificbiomarkersthanMA[9].Someprevious-ly published reviews have focused on the methodologicalaspects of proteomics [10,11] or on the approaches for dis-coveringandvalidatingdiagnosticmarkers[12,13].Aspro-teomics studies devoted to DN biomarker discovery begantobepublishedin2004[14],inthisarticle,wewillcompre-hensively review the available information published sincethen.Targeting DN biomarkers: an overview of the experimentalmethodsTable 1 summarizes the key information available from theanalysis of the literature. Urine is the biological fluid thatattracted most of the interest in the proteomic quest of DNbiomarkers. This makes sense because the protein compos-ition of urine might correctly reflect the renal functionalabnormalities associated with DN [15]. Moreover, urinehas some unique advantages such as its availability in largequantities as well as the solubility and stability of its pro-tein content [16]. Nevertheless, serum from type 2 diabeticpatients (four studies) [17–20] and pooled haemofiltratesfrom patients suffering from chronic renal insufficiency(most of them were also diabetics) (one work) [21] werealso analysed.Concerning the choice of separation and identificationtechniques (Table 1), two-dimensional gel electrophoresis(2D-GE) was frequently employed (however in differentexperimental set-ups). This is likely due to the fact that2D-GE easily provides a semi-quantitative estimation ofthe amount of each separated protein (spot intensity) andsome qualitative information about the size and the post-translational modifications of such proteins. These positivefeatures compensate for the limitations of 2D-GE such aslow throughput and a possible lack of sensitivity. Profilingmethods were chosen for several studies (indicated inTable 1). They generate a list of mass peaks which needthen to be assigned to a specific peptidic/protein se-quence. Surface-enhanced laser desorption/ionizationtime-of-flight (SELDI-TOF) mass spectrometry (a prote-omic method that enables mass fingerprinting of proteinsretained onto an affinity chip) was used in four differentstudies [18,22–24]. Interestingly, in each work, a differentseparationsurface(ProteinChip)wasconsideredasthemost" @default.
• W2108709967 created "2016-06-24" @default.
• W2108709967 creator A5003717230 @default.
• W2108709967 creator A5003809574 @default.
• W2108709967 creator A5013168550 @default.
• W2108709967 creator A5022608083 @default.
• W2108709967 creator A5040653950 @default.
• W2108709967 creator A5061468431 @default.
• W2108709967 creator A5070559991 @default.
• W2108709967 creator A5080213007 @default.
• W2108709967 date "2010-05-14" @default.
• W2108709967 modified "2023-10-18" @default.
• W2108709967 title "Proteomic approaches for discovering biomarkers of diabetic nephropathy" @default.
• W2108709967 cites W1573949755 @default.
• W2108709967 cites W1967716372 @default.
• W2108709967 cites W1970900188 @default.
• W2108709967 cites W1973406559 @default.
• W2108709967 cites W1980649172 @default.
• W2108709967 cites W1981410669 @default.
• W2108709967 cites W1982092732 @default.
• W2108709967 cites W1990056595 @default.
• W2108709967 cites W1992136146 @default.
• W2108709967 cites W2006939427 @default.
• W2108709967 cites W2009355247 @default.
• W2108709967 cites W2021420773 @default.
• W2108709967 cites W2021787484 @default.
• W2108709967 cites W2023812518 @default.
• W2108709967 cites W2023850695 @default.
• W2108709967 cites W2033503356 @default.
• W2108709967 cites W2035540717 @default.
• W2108709967 cites W2045153875 @default.
• W2108709967 cites W2054801022 @default.
• W2108709967 cites W2056499488 @default.
• W2108709967 cites W2060813860 @default.
• W2108709967 cites W2063083371 @default.
• W2108709967 cites W2069129324 @default.
• W2108709967 cites W2070642086 @default.
• W2108709967 cites W2071858341 @default.
• W2108709967 cites W2075911589 @default.
• W2108709967 cites W2082206313 @default.
• W2108709967 cites W2098129643 @default.
• W2108709967 cites W2098951852 @default.
• W2108709967 cites W2105130711 @default.
• W2108709967 cites W2107031719 @default.
• W2108709967 cites W2112894886 @default.
• W2108709967 cites W2113184926 @default.
• W2108709967 cites W2115498556 @default.
• W2108709967 cites W2119652593 @default.
• W2108709967 cites W2122202606 @default.
• W2108709967 cites W2129062330 @default.
• W2108709967 cites W2132991599 @default.
• W2108709967 cites W2133339990 @default.
• W2108709967 cites W2136704137 @default.
• W2108709967 cites W2140617063 @default.
• W2108709967 cites W2142067231 @default.
• W2108709967 cites W2143616363 @default.
• W2108709967 cites W2144164915 @default.
• W2108709967 cites W2147524926 @default.
• W2108709967 cites W2148342716 @default.
• W2108709967 cites W2317521667 @default.
• W2108709967 cites W2751771006 @default.
• W2108709967 cites W3021707179 @default.
• W2108709967 cites W3034899365 @default.
• W2108709967 cites W4230176558 @default.
• W2108709967 cites W4234254760 @default.
• W2108709967 doi "https://doi.org/10.1093/ndt/gfq258" @default.
• W2108709967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20472580" @default.
• W2108709967 hasPublicationYear "2010" @default.
• W2108709967 type Work @default.
• W2108709967 sameAs 2108709967 @default.
• W2108709967 citedByCount "41" @default.
• W2108709967 countsByYear W21087099672012 @default.
• W2108709967 countsByYear W21087099672013 @default.
• W2108709967 countsByYear W21087099672014 @default.
• W2108709967 countsByYear W21087099672015 @default.
• W2108709967 countsByYear W21087099672016 @default.
• W2108709967 countsByYear W21087099672017 @default.
• W2108709967 countsByYear W21087099672020 @default.
• W2108709967 crossrefType "journal-article" @default.
• W2108709967 hasAuthorship W2108709967A5003717230 @default.
• W2108709967 hasAuthorship W2108709967A5003809574 @default.
• W2108709967 hasAuthorship W2108709967A5013168550 @default.
• W2108709967 hasAuthorship W2108709967A5022608083 @default.
• W2108709967 hasAuthorship W2108709967A5040653950 @default.
• W2108709967 hasAuthorship W2108709967A5061468431 @default.
• W2108709967 hasAuthorship W2108709967A5070559991 @default.
• W2108709967 hasAuthorship W2108709967A5080213007 @default.
• W2108709967 hasConcept C134018914 @default.
• W2108709967 hasConcept C2779922275 @default.
• W2108709967 hasConcept C2781184683 @default.
• W2108709967 hasConcept C555293320 @default.
• W2108709967 hasConcept C60644358 @default.
• W2108709967 hasConcept C70721500 @default.
• W2108709967 hasConcept C71924100 @default.
• W2108709967 hasConcept C86803240 @default.
• W2108709967 hasConceptScore W2108709967C134018914 @default.
• W2108709967 hasConceptScore W2108709967C2779922275 @default.
• W2108709967 hasConceptScore W2108709967C2781184683 @default.

• next